Man Group’s Oric Pharmaceuticals ORIC Stock Holding History

Man Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,209	Closed	-$58.6K	–	1816
2022 Q4	$66K	Buy	+11,209	New	+$37.8K	﹤0.01%	1949

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Man Group's ORIC Position: Q1 2023 in Review

Man Group sold out of Oric Pharmaceuticals (ORIC) in Q1 2023, closing a stake of 11,209 shares — an estimated $58.6K sold.

Man Group first reported a position in ORIC in Q4 2022 and held it in 1 quarter. The position peaked at $66K in Q4 2022. 70 funds tracked by Wall St. Rank hold ORIC as of Q1 2023.

Man Group reported no remaining Oric Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Man Group sold 11,209 Oric Pharmaceuticals shares in Q1 2023, an estimated $58.6K.
Man Group first reported a position in Oric Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Man Group's Oric Pharmaceuticals position peaked at $66K in Q4 2022.
70 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.